Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, raised $108 million by offering 6 million shares (vs. 5 million originally planned) at $18, the high end of the $16 to $18 range. Ascendis Pharma will list on the NASDAQ under the symbol ASND. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint bookrunners on the deal.
